Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yeming, Zhou, Fei, Zhang, Dingyu, Zhao, Jianping, Du, Ronghui, Hu, Yi, Cheng, Zhenshun, Gao, Ling, Jin, Yang, Luo, Guangwei, Fu, Shouzhi, Lu, Qiaofa, Du, Guanhua, Wang, Ke, Lu, Yang, Fan, Guohui, Zhang, Yi, Liu, Ying, Ruan, Shunan, Liu, Wen, Jaki, Thomas, Hayden, Frederick G., Horby, Peter W., Cao, Bin, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245636/
https://www.ncbi.nlm.nih.gov/pubmed/32448345
http://dx.doi.org/10.1186/s13063-020-04352-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245636/
https://www.ncbi.nlm.nih.gov/pubmed/32448345
http://dx.doi.org/10.1186/s13063-020-04352-9

Ejemplares similares